logo
Fears of US public health crises grow amid falling vaccination rates

Fears of US public health crises grow amid falling vaccination rates

Yahoo25-02-2025

Plummeting immunization rates, outbreaks of once-vanquished childhood diseases, and the appointment of a vocal vaccine skeptic as health secretary have US experts sounding the alarm about a looming public health crisis.
Since the start of the year, nearly 100 cases of measles have been reported in Texas and neighboring New Mexico, raising fears that the highly contagious and potentially serious illness is making a comeback.
"The measles is the canary in the coal mine," warned leading pediatrician and immunologist Paul Offit, highlighting the decline in vaccination rates since the Covid-19 pandemic.
Amid growing distrust of health authorities and pharmaceutical companies, more parents are opting not to vaccinate their children.
The proportion of preschool-aged children vaccinated against measles -- which is mandatory -- has dropped nationally from 95 percent in 2019 to less than 93 percent in 2023. Some regions show even steeper declines, such as Idaho, where rates have fallen below 80 percent.
Experts warn that this trend could worsen under the leadership of newly appointed Health Secretary Robert Kennedy Jr., who has repeatedly questioned vaccine safety and promoted misinformation.
"It is a disaster waiting to happen, and it will happen," Offit told AFP.
- Religious exemptions -
In Louisiana, whooping cough has resulted in the deaths of two children, according to local media. As with measles, experts attribute the resurgence to vaccine exemptions.
"This is already happening. Our immunization rates are already low enough that vulnerable children are getting these diseases," said Jennifer Herricks, a scientist and board member of the nonprofit Louisiana Families for Vaccines, in an interview with AFP.
Across much of the country, parents can opt out of mandatory vaccinations for reasons beyond medical contraindications.
Many states allow exemptions on religious grounds, while others permit "philosophical" objections -- or both.
"In Texas, you can just, pretty much say, I object," explained Terri Burke of the Texas-based Immunization Partnership.
The recent measles cases have been reported in a Texas county with a large Mennonite population -- a conservative Christian sect.
The situation is reminiscent of the 2019 measles outbreak, which saw more than 1,200 cases, primarily among unvaccinated Orthodox Jewish communities in New York and New Jersey.
While the reasons behind these exemptions vary -- ranging from religious beliefs and fear of side effects to distrust in health authorities or difficulties accessing health care -- there is an undeniable trend linked to a "pandemic backlash," said Richard Hughes, a health policy expert at George Washington University.
- Legislative offensives -
Mixed messaging on masking, frustration over lockdowns and Covid vaccine mandates -- some of which remained in place long after it was clear the shots didn't fully prevent transmission -- have eroded public trust, he said.
"We might have done better by just continuing to encourage people to be vaccinated than requiring it," Hughes added.
But any missteps were amplified by an overwhelming spread of misinformation, which thrived in the era of social media and podcasts.
These factors have turned vaccinations into a flashpoint in America's culture wars. Across the country, lawmakers are introducing bills aimed at either enshrining vaccine mandates at the local level, banning certain types of vaccines, or expanding exemptions.
The number of such bills has more than doubled compared to pre-Covid levels, said Herricks, who tracks the issue nationally.
Notable shifts include Montana's decision to halt vaccination statistics and Louisiana's cessation of vaccine promotion -- both signs of the growing marginalization of a practice that was once a cornerstone of public health policy.
According to Offit, Americans may soon face a harsh reality check.
Before the measles vaccine was introduced in 1963, the disease sickened an estimated three to four million Americans annually and killed hundreds.
It was declared eliminated in the United States by 2000, thanks to widespread immunization.
"People don't realize how sick and dead that virus can make you," he said.
cha/ia/jgc

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

time29 minutes ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

CDC firings: Former director, fired vaccine panelist on RFK Jr's changes
CDC firings: Former director, fired vaccine panelist on RFK Jr's changes

Yahoo

time44 minutes ago

  • Yahoo

CDC firings: Former director, fired vaccine panelist on RFK Jr's changes

(NewsNation) — While Health and Human Services Secretary Robert F. Kennedy Jr. says he wanted to restore public trust by firing the entire vaccine advisory panel at the Centers for Disease Control and Prevention, one person he fired says Kennedy did the opposite in the academic community. The Advisory Committee on Immunization Practices members was made up of medical and health professionals who made recommendations on the safety and use of vaccines. One of the 17 panelists fired is Dr. Noel Brewer, who joined NewsNation's 'CUOMO' on Tuesday night. 'My concern is that we've taken 60 years of efforts to build trust among health care providers in the recommendations of the advisory committee through CDC, and that trust just evaporated overnight,' Brewer said. 'It is going to be hard to get that back.' The committee was set to meet in two weeks to discuss COVID-19 and other vaccines. Judge determined OPM broke law with DOGE access to data 'I don't think most Americans even care that much about it. And now that there's all this news and people like me out from our ivory towers, it's generating interest,' Brewer said. 'But I don't think that the impact here is going to be primarily among the general public.' Dr. Robert Redfield was CDC director under the first Trump administration, and he said the public lost trust in the power of vaccines. 'I believe vaccines are the most important gift of science to modern medicine. When I was CDC director, I was very disturbed that over half of the population didn't get the flu vaccine,' he said. 'Then, the COVID pandemic came, and I have to say, although I have a lot of respect for Noel and the other people on the committee, the reality is the guidance that came out of the ACIP for COVID vaccines, I think in general, was ill-advised.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Mailed Kits Beat Office Visits for Cervical Cancer Screening
Mailed Kits Beat Office Visits for Cervical Cancer Screening

Medscape

time2 hours ago

  • Medscape

Mailed Kits Beat Office Visits for Cervical Cancer Screening

Mailed self-collection kits and a telephone reminder helped increase cervical cancer screening (CCS) rates more than twice as much as telephone reminders for an office visit, according to new data from a randomized clinical trial in a safety-net population. The home kits paired with additional patient contact increased numbers even further. In a trial that included 2474 people overdue for CCS (94% of them from minority populations), participants randomized to a telephone reminder with a mailed self-collection kit had 41.1% participation compared to those with a phone reminder to come in for an office visit (17.4%). CCS rates were modestly higher (46.6%) when people received contact in addition to the telephone reminder and mailed self-collection kit for testing human papillomavirus (HPV). Self-collection with additional patient contact was designed to be different from self-collection with a telephone reminder in terms of the dose of patient interactions rather than content, minimizing potential contamination across the self-collection with telephone reminder and self-collection with additional patient contact groups. The study, led by Jane R. Montealegre, PhD, with the Department of Behavioral Science, The University of Texas MD Anderson Cancer Center in Houston, was conducted from February 20, 2020, to August 31, 2023, and published in JAMA Internal Medicine . Cervical Cancer Could be Eliminated in the US in 10-20 Years Estimates show that cervical cancer in the US could see national-level elimination in the next one to two decades if CCS rates hit 90%. However up-to-date screening has declined in recent years and was 75.2% in 2021, with rates notably lower among underserved populations, including women and people with a cervix who are uninsured or publicly insured, live in rural areas, and are from minority populations. The study researchers noted that the results in this trial, the PRESTIS trial, are consistent with the relative participation rates of previous trials. In a recent meta-analysis of 28 trials, Stefanie Costa and colleagues reported a 2.5-fold higher participation in screening with mailed self-collection vs usual care. 'Notably distinct from previous trials are the large screening proportions attained in the [self-collection (SC) group] (41.1%) and SC with patient navigation (46.6%) groups, as compared to the global estimate of 24% reported in the meta-analysis,' the authors wrote. In an accompanying editorial, Eve Rittenberg, MD, MA, with the Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues wrote that home self-collection 'has the potential to meaningfully reduce cervical cancer burden, especially among underserved populations.' They pointed out that self-collection has previously been studied in a clinical setting, where women can collect a sample privately without undergoing an invasive Pap smear and that 'self-collected HPV samples have similar specificity and sensitivity to clinician-collected samples.' But it hasn't been known whether the tests need to be performed in a clinic. Home Screening May Further Eliminate Barriers Montealegre's team shows that 'home self-collection demonstrates that people can adequately obtain usable samples in the privacy of their homes, as only 6% of samples were deemed inadequate for evaluation,' the editorialists wrote. Home-based screening, they explained, may further eliminate screening barriers for underserved populations with lower costs and fewer logistical hurdles. Additionally, screening via pelvic exam can be uncomfortable and may be culturally unacceptable for some. Pelvic exam-based screening may be particularly distressing to those who have experienced sexual trauma, they wrote. They pointed out that options for CCS are growing with the approval last month by the FDA of a home HPV self-collection kit, which will be available for clinical use within months. Self-collection of HPV samples is included in the World Health Organization's global strategy to eliminate cervical cancer by 2030, and the draft US Preventive Services Task Force CCS guidance now includes self-collection as an option. Future research should help determine whether more home self-collected HPV screening leads to higher rates of treating precancerous lesions and eventually lower cervical cancer rates, the editorialists wrote. They also noted that efforts to increase CCS rates should be accompanied by efforts to increase HPV vaccination rates. The research was funded through grants from the National Institute on Minority Health and Health Disparities and the National Cancer Institute through an MD Anderson Cancer Center Support Grant, the Dan L Duncan Comprehensive Cancer Center Support Grant, and the Hollings Cancer Center Support Grant. The authors reported having no relevant financial relationships. An editorialist, Cary Gross, MD, reported receiving grants from Johnson & Johnson and the National Comprehensive Cancer Network (with funding provided by AstraZeneca) outside the submitted work. No other disclosures were reported.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store